Regaining compliance with Nasdaq's minimum bid price requirement is a positive development for NeuroBo Pharmaceuticals. It removes the immediate risk of delisting, which can be a significant concern for investors and can affect the stock's liquidity and attractiveness. This news is likely to be viewed positively by the market in the short term, potentially leading to an increase in investor confidence and an uptick in the stock price.